Business Development

Contact: Annabelle Lim, Ph.D / Ong Siew Min, Ph.D
Email: /

The Business Development and Industry Engagement Group provides core support to the SIgN Principal Investigators for the development and formalisation of translational projects with industry, clinical partners and public sector performers.

In addition, the Group oversees activities related to business development, contracts management, scientific intellectual property management as well as management of institute-wide IRB study.

The Group works hand-in-hand with the Innovation and Enterprise (I&E) Group and A*ccelerate Technologies (A*STAR’s commercialization arm) to identify and market relevant SIgN expertise, matching it with Industry needs to facilitate partnerships with research community in Singapore and beyond.


SIgN is open to a variety of engagement models with industry partners, but prioritizes collaborations based on common scientific interests and shared contributions. This often involves co-development of new products or technologies, and/or establishment of clinical research in the immunology space. In addition to research collaborations, SIgN has established 6 joint laboratories with industry collaborators, to help anchor and grow their R&D programs within Singapore, resulting in value creation. Building on the capabilities of SIgN’s Immunomonitoring Platform capabilities, we have also attracted 5 foreign technology companies to set up Centres of Excellence at SIgN to make available their emerging technologies and capabilities to the local R&D community.

In addition to partnering with industry partners, SIgN actively collaborates with local research institutes, hospitals and universities to add value to strategic research programs that give Singapore a competitive advantage in global research. 


Leveraging on our R&D scientific excellence, SIgN has produced three spin-off companies in the technology and therapeutics space, namely ImmunoScape, Euchloe Bio and Twain Therapeutics.